Morphic Therapeutic, Inc.
https://morphictx.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Morphic Therapeutic, Inc.
Lilly To Bolster IBD Pipeline With $3.2bn Morphic Bid
With only one inflammatory bowel disease product, Lilly is betting big on Morphic and its Phase II oral integrin MORF-057, which would directly compete with Takeda blockbuster Entyvio.
Ensho Joins Race To Develop An Oral Integrin Inhibitor For IBD
Ensho Therapeutics is raising series A cash to develop Phase II-ready NSHO-101 (EA1080), a third oral ɑ4β7 integrin inhibitor attempting to take on Takeda’s blockbuster injectable Entyvio.
Abivax Confident About Securing Success Stateside
The French group has just listed on the NASDAQ and while its stock has already taken a couple of hits, CEO Marc de Garidel has faith that the firm’s IBD drug obefazimod will be a major player in the space.
How The Allure Of Abivax Kept Marc de Garidel From The Beach
Abivax has had its ups and downs but newly appointed CEO Marc de Garidel tells Scrip he is confident that the French group is onto a winner with its ulcerative colitis drug, obefazimod.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Morphic Holding, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice